Provectus Biopharmaceuticals, Inc. — Cash Flow Charts
8 quarters of history · ending 2025-12-31 · SEC EDGAR
Source:10-K · 10-Q
Capital Allocation
How management deploys cash: investing in the business (Capex + M&A) vs returning to shareholders (Buybacks + Dividends).
Buybacks vs Stock-Based Comp
Cash Flow
Cash Flow by Activity
Operating Cash Flow↓-4.7% -$49K
$-1M
Free Cash Flow↓-4.7% -$49K
$-1M
Investing Cash Flow
—
Financing Cash Flow↑+33.0% +$260K
$1M
Capex
—
Stock Buybacks
—
Stock-Based Comp↓-77.5% -$990K
$288K
D&A↓-0.2% -$1
$465
SBC Allocated Expense↑+179.1% +$593K
$925K